Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Neuro-Oncology|August 5, 2020
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomesNoa G Holtzman, Hao Xie, Soren Bentzen, et al.
Blood Cancer Journal|May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell LymphomaVictor Yazbeck, Danielle Shafer, Edward B Perkins, et al.
Leukemia & Lymphoma|March 28, 2015
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaRuben Niesvizky, Ashraf Z Badros, Luciano J Costa, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.
Pageof 5